Malignant bone tumors

Journal of Bone and Joint Surgery

Volumn 83, Issue 11, 2001, Pages 1728-1745

  Gibbs C P , Jr ^a   Weber, K ^a   Scarborough, M T ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; COLLAGENASE; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; MULTIDRUG RESISTANCE PROTEIN; PROTEIN P53; RETINOBLASTOMA PROTEIN; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VASCULOTROPIN RECEPTOR; VINCRISTINE;

ANGIOGENESIS; BONE RADIOGRAPHY; BONE TUMOR; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CHONDROSARCOMA; CLEAR CELL SARCOMA; CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; CYTOGENETICS; EWING SARCOMA; EXOSTOSIS; HUMAN; MESENCHYMOMA; ONCOGENE; OSTEOSARCOMA; PRIORITY JOURNAL; PROGNOSIS; TUMOR SUPPRESSOR GENE;

EID: 0035181557     PISSN: 00219355     EISSN: None     Source Type: Journal    
DOI: 10.2106/00004623-200111000-00019     Document Type: Conference Paper

References (95)

1. Epidemiology of osteosarcoma and Ewing's sarcoma in childhood: A study of 305 cases by the Children's Cancer Group
2. The Li-Fraumeni syndrome: An inherited susceptibility to cancer
3. Outcome of patients with a history of bilateral retinoblastoma treated for a second malignancy: The Memorial Sloan-Kettering experience
4. Post-radiation sarcomas: A review of the clinical and imaging features in 63 cases
5. Malignant transformation in Paget disease of bone
6. Initial symptoms and clinical features in osteosarcoma and Ewing sarcoma
7. Prognostic significance of serum lactate dehydrogenase in patients with osteosarcoma of the extremities
8. Prognostic value of serum alkaline phosphatase in osteosarcoma
9. Current concepts review. Evaluation and staging of musculoskeletal neoplasms
10. Staging of intraosseous extent of osteosarcoma: Correlation of preoperative CT and MR imaging with pathologic macroslides
11. Prognosis for patients who have osteosarcoma with skip metastasis
12. Parosteal osteosarcoma. A clinicopathological study
13. Dedifferentiated parosteal osteosarcoma
14. Conventional and dedifferentiated parosteal osteosarcoma. Diagnosis, treatment, and outcome
15. Periosteal osteosarcoma
16. High-grade surface osteosarcoma: A clinicopathologic study of 46 cases
17. Amputation and adriamycin in primary osteosarcoma
18. Adjuvant methotrexate and citrovorum-factor treatment of osteogenic sarcoma
19. A controlled pilot study of high-dose methotrexate as postsurgical adjuvant treatment for primary osteosarcoma
20. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity
21. Adjuvant chemotherapy for osteosarcoma: A randomized prospective trial
22. Primary osteogenic sarcoma: The rationale for preoperative chemotherapy and delayed surgery
23. Treatment of nonmetastatic osteosarcoma of the extremity with preoperative postoperative chemotherapy: A report from the Children's Cancer Group
24. Neoadjuvant chemotherapy of osteosarcoma: Results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response
25. Limb salvage compared with amputation for osteosarcoma of the distal end of the femur. A long-term oncological, functional, and quality-of-life study
26. Survival, prognosis, and therapeutic response in osteogenic sarcoma. The Memorial Hospital experience
27. Osteogenic sarcoma of the extremity with detectable lung metastases at presentation. Results of treatment of 23 patients with chemotherapy followed by simultaneous resection of primary and metastatic lesions
28. Osteogenic sarcoma with clinically detectable metastasis at initial presentation
29. Pulmonary metastases of stage IIB extremity osteosarcoma and subsequent pulmonary metastases
30. Prognostic factors in osteosarcoma: A critical review
31. Oncologic outcomes of primary bone sarcomas of the pelvis
32. Allelotype analysis in osteosarcomas: Frequent allele loss on 3q, 13q, 17p, and 18q
33. Mutation spectrum of the retinoblastoma gene in osteosarcomas
34. Loss of heterozygosity of the RB gene is a poor prognostic factor in patients with osteosarcoma
35. Localization of a novel tumor suppressor locus on human chromosome 3q important in osteosarcoma tumorigenesis
36. Alterations of the p53, Rb, and MDM2 genes in osteosarcoma
37. p53 and MDM2 alterations in osteosarcomas: Correlation with clinicopathologic features and proliferative rate
38. C-myc and c-fos in human osteosarcoma: Prognostic value of mRNA and protein expression
39. Expression of HER2/erbB-2 correlates with survival in osteosarcoma
40. ErbB-2 expression is correlated with poor prognosis for patients with osteosarcoma
41. P-glycoprotein expression in osteosarcoma: A basis for risk-adapted adjuvant chemotherapy
42. Relationship between P-glycoprotein expression and p53 status in high-grade osteosarcoma
43. MDR1 gene expression and outcome in osteosarcoma: A prospective, multicenter study
44. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice
45. Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis
46. The Ewing family of tumors. Ewing's sarcoma and primitive neuroectodermal tumors
47. Ewing's sarcoma
48. Ewing sarcoma family of tumors
49. Preoperative evaluation and monitoring chemotherapy in patients with high-grade osteogenic and Ewing's sarcoma: Review of current imaging modalities
50. Ewing's sarcoma of bone: Clinicopathologic aspects of 303 cases from the Intergroup Ewing's Sarcoma Study
51. EWS-FLI1, EWS-ERG, and EWS-ETV1 oncoproteins of Ewing tumor family all suppress transcription of transforming growth factor beta type II receptor gene
52. Long-term results in 144 localized Ewing's sarcoma patients treated with combined therapy
53. Multimodal therapy for the management of nonpelvic, localized Ewing's sarcoma of bone: Intergroup study IESS-II
54. Ifosfamide-containing chemotherapy in Ewing's sarcoma: The Second United Kingdom Children's Cancer Study Group and the Medical Research Council Ewing's Tumor Study
55. Adding ifosfamide and etoposide to vincristine, cyclophosphamide, adriamycin, and actinomycin improves outcome in non-metastatic Ewing's and PNET: Update of CCG/POG study
56. Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: A long-term follow-up of the first intergroup study
57. Ifosfamide and etoposide plus vincristine, doxorubicin, and cyclophosphamide for newly diagnosed Ewing's sarcoma family of tumors
58. Diffuse endothelioma of bone
59. The Ewing family of tumors - A subgroup of small-round-cell tumors defined by specific chimeric transcripts
60. Immunostaining of the p30/32MIC2 antigen and molecular detection of EWS rearrangements for the diagnosis of Ewing's sarcoma and peripheral neuroectodermal tumor
61. Multimodal therapy for the management of localized Ewing's sarcoma of pelvic and sacral bones: A report from the second intergroup study
62. Prognostic factors in Ewing's tumor of bone: Analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group
63. Prognostic factors in patients with localized Ewing's sarcoma: The effect on survival of actual received drug dose intensity and of histologic response to induction therapy
64. Ewing's sarcoma. Prognostic factors, disease control, and the re-emerging role of surgical treatment
65. Significance of surgical margin on the prognosis of patients with Ewing's sarcoma. A report from the Cooperative Ewing's Sarcoma Study
66. Prognostic significance of histopathologic response to chemotherapy in nonmetastatic Ewing's sarcoma of the extremities
67. The histological response to chemotherapy as a predictor of the oncological outcome of operative, treatment of Ewing sarcoma
68. Ewing's sarcoma of bone. Experience with 140 patients
69. Ewing's sarcoma: Surgical resection as a prognostic factor
70. Ewing's sarcoma. Radiotherapy versus surgery for local control
71. Effects of radiation therapy on skeletal growth in childhood
72. Second malignancies after Ewing's sarcoma: Radiation dose-dependency of secondary sarcomas
73. Bone sarcomas linked to radiotherapy and chemotherapy in children
74. Vascularized free fibular transfer combined with autografting for the management of fracture nonunions associated with radiation therapy
75. Ewing's sarcoma of the proximal femur
76. Ewing sarcoma of the pelvis. Clinicopathological features and treatment
77. Role of surgical resection in pelvic Ewing's sarcoma
78. Primary Ewing's sarcoma of the spine
79. Ewing's sarcoma of the vertebral column
80. Tumors of cartilage origin
81. Cartilage tumors: Evaluation and treatment
82. Unusual types of chondrosarcoma
83. Chondrosarcoma: Clear-cell variant. A report of sixteen cases
84. Dedifferentiated chondrosarcoma. A report of the clinicopathological features and treatment of seventy-eight cases
85. Dedifferentiation of low-grade chondrosarcomas
86. Musculoskeletal oncology - Advances in cytogenetics and molecular genetics and their clinical implications
87. Marshall Urist Award. Interstitial collagenase gene expression correlates with in vitro invasion in human chondrosarcoma
88. Overexpression of cathepsin B and urokinase plasminogen activator is associated with increased risk of recurrence and metastasis in patients with chondrosarcoma